Compare GMED & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMED | ROIV |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 14.1B |
| IPO Year | 2012 | N/A |
| Metric | GMED | ROIV |
|---|---|---|
| Price | $94.34 | $21.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $92.42 | $24.31 |
| AVG Volume (30 Days) | 1.3M | ★ 8.4M |
| Earning Date | 02-19-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 358.86 | N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | ★ $2,769,804,000.00 | $20,329,000.00 |
| Revenue This Year | $16.86 | N/A |
| Revenue Next Year | $8.05 | $741.42 |
| P/E Ratio | $29.40 | ★ N/A |
| Revenue Growth | ★ 11.75 | N/A |
| 52 Week Low | $51.79 | $8.73 |
| 52 Week High | $94.93 | $23.47 |
| Indicator | GMED | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 65.50 | 53.52 |
| Support Level | $90.01 | $21.15 |
| Resistance Level | $94.51 | $22.14 |
| Average True Range (ATR) | 2.40 | 0.65 |
| MACD | 0.17 | -0.13 |
| Stochastic Oscillator | 56.33 | 52.76 |
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.